

Lupin wins Ramipril product patent challenge at Federal Circuit

BSE: 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------------	-------------------	-------------------------	--------------------------

Mumbai, 12 September 2007: Lupin Ltd. (Lupin), today announced that the Court of Appeals for the Federal Circuit yesterday reversed a district court decision on Ramipril in its favor, finding the Aventis patent on Ramipril invalid. Aventis owns the '722 patent in question and King Pharmaceuticals markets Altace.

Ramipril is one of the ACE inhibitors, which are useful for treating high blood pressure and Altace revenues were over USD 900 million in the US (IMS MAT Jun 2007).

“We are really pleased that we won the appeal,” said Dr. Kamal K. Sharma, Managing Director, Lupin “We are in the process of determining when we can enter the market. We believe that this is a land-mark decision and is strong testament of our IP capabilities”.

About Lupin

Headquartered in Mumbai, Lupin is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the quarter ended June 2007, Lupin’s Revenues and Profit after Tax were Rs.6173 million (US\$ 152 million) and Rs.784 million (US\$ 19 million) respectively.

For further information contact:

Raju Kane

The Source

Tel. +91 22 24901327/28

Telefax: +91 22 24901325

Mobile: +91 98200 45656

E-mail: rajukane@sourcepr.com